PinPointe Foot Laser

PinPointe™ FootLaser™ - The only laser with clinically proven efficacy and FDA clearance for onychomycosis.

PinPointe™ FootLaser™ is the first laser scientifically designed to promote clear nail in patients who suffer from unsightly nail fungus. Clinically proven, this is without the harmful side effects of oral medications, and typically takes only 30-minutes to perform.

Stop suffering the pain and embarrassment of unsightly nail fungus. PinPointe FootLaser is the easy and convenient treatment that helps turn your discolored and disfigured nails into clearer, healthier looking nails.

Give your feet something to smile about from toe to toe. Treat them to the PinPointe FootLaser and see how exciting it feels to look so good.


PinPointe Toe Fungus Treatment Featured on The Doctors

Pinpointe FootLaser

PinPointe FAQ's

Q: How does the PinPointe FootLaser work?
A: The PinPointe FootLaser kills fungus that lives in and under the nail. The laser light passes through
the nail without causing damage to the nail or the surrounding skin. At the time of the procedure, the
toenail will not become instantly clear— it takes time to grow out.

Q: What can I expect in the provider’s office?
A: The process begins with a consultation in which your provider, who will explain the procedure that is
to be performed and any follow-up visits that may be required.

Q: Is the procedure painful?
A: Most patients feel no pain. Some may feel a warming sensation. An isolated few may feel a slight

Q: Is there a recovery period?
A: No. The treatment is a walk in/walk out procedure.

Q: How long does the procedure take?
A: The PinPointe FootLaser procedure typically takes about 30 minutes.

Q: Will the fungus grow back?
A: The infection improves after one treatment. However, there is a chance of reinfection because the
fungus is present everywhere in the environment. Your will recommend care techniques to help reduce a
recurrence of the infection.

Q: When is it safe to paint my nails or have a pedicure following treatment?
A: You can apply polish immediately after the treatment. It is important that you remove all nail polish
and nail decorations the day before your treatment.

Q: Is the procedure covered by insurance?
A: This procedure is considered aesthetic and therefore health insurance does not provide coverage.

Q: How long has the PinPointe FootLaser been in use?
A: Clinical studies began in November 2007.

Q: Is the PinPointe FootLaser FDA cleared?
A: Yes, the device has received FDA clearance.

Q: Who developed the PinPointe FootLaser procedure?
A: Leading scientists and medical professionals working together for 20 years with funding provided by
the National Institutes of Health developed the technology used in the patented PinPointe FootLaser

For more information please visit the PinPointe FootLaser website.

White Paper
MicroPulsed Nd:YAG Laser in
the Treatment of Onychomycosis

Martine and Michael Abrahams
London Nail Laser Clinic


Purpose: To evaluate the efficacy of PinPointe™ FootLaser™ for the treatment of onychomycosis.

Design: A retrospective study of 12 subjects presenting with onychomycosis received treatment with the PinPointe micropulsed Nd:YAG laser. Baseline and post follow-up photographs were taken to compare response rate. Planimetry using ImageJ software was used to calculate clear nail growth and lesion reduction.

Results: 100% of subjects responded to treatment. Subjects receiving one treatment achieved a 60% reduction in lesion area and 77% clear nail at follow up. Post one treatment, subjects showed 50% absolute clear nail growth. Subjects receiving up to three treatments achieved a 71% reduction in lesion area and 71% clear nail at follow up. Subjects who received multiple treatments showed 70% absolute clear nail growth, as compared to 50% for subjects who received one treatment.

Conclusions: PinPointe FootLaser is effective for the treatment of onychomycosis. Subjects receiving multiple treatments achieved better results than those receiving only one treatment.


Onychomycosis is a common nail disorder affecting between 2-28% of the population and its prevalence appears to be increasing.1,2 This infection is most prevalent in those who are immunosuppressed, individuals who experience frequent nail damage and the elderly
–affecting up to 40% of this population.3

Dermatophytes, a homogeneous group of keratinophilic fungi, are the cause of over 90% of all cases of onychomycosis.4 The most common dermatophytes are Trichophyton rubrum and Trichophyton mentagrophytes. Additionally, Candida species and non-dermatophytic molds (NDMs) have also been implicated in the cause of onychomycosis.

For those who are effected, onychomycosis can lead to additional medical, social and emotional issues. The primary concerns among subjects include the spread of infection to other nails or to other people, and others noticing the deformed nail(s). This can lead to a lowered self-esteem, poor body image, and depression. Physical problems associated with onychomycosis include difficulties with walking, pain, discomfort, trouble with clipping nails, and risk of acute bacterial cellulitis.7,8 Thus, onychomycosis is of considerable concern to the population.

Today, three main methods, topical, oral and devicerelated therapies, are currently employed to treat onychomycosis.

Oral treatments, such as Terbinafine, Itraconazole, Fluconazole, Griseofulvin, Ketoconazole, Posaconazole, and Ravuconazole, interfere with ergosterol synthesis in fungi, halting their growth. Terbinafine, for example, is an allylamine derivative, interfering with fungal cell membrane synthesis and causing fungal toxicity. However, treatment with Terbinafine does pose the risk of potential side effects including gastrointestinal disturbances, 11,12 skin rashes,13 pancytopenia, agranulocytosis, drug interactions and drug resistance; and its efficacy remains limited. Other oral medications such as Itraconazole (a fungistatic triazole14), and Ketoconazole can produce significant adverse effects, including severe liver injury.15 Patients who choose oral drug therapies are required to undergo frequent blood testing and must refrain from alcohol consumption during the entire course of treatment.

Topical therapies have become increasingly popular because they pose none of the adverse effects associated with systemic treatment. Topical therapies include Ciclopirox, Amorolofine, Imidazoles, Tolnaftate, Bifenafine, Tioconazole, and topical Terbinafine. With the introduction of trans-ungual delivery, chemical penetration enhancers, bioadhesive polymers, surface modifiers and ultrasound,16 their efficacy seems to be improving. Topical treatments do not perform well when there is multiple nail involvement, or involvement of more than the distal two-thirds of the nail plate or lunula. Additionally, since these topical therapies do not penetrate the nail plate, efficacy is low and recurrence is high.

Device-related therapies such as chemical or surgical debridement as well as laser therapies have become increasingly popular in the treatment of onychomycosis. Laser treatments not only provide aesthetic benefits to the majority of subjects,18 but they are also effective in clearing the infection by causing photoinactivation of the fungi, inhibiting fungal cell growth.19, 20, 21 This study evaluates the efficacy of the PinPointe FootLaser as a valuable treatment option for the management of onychomycosis.


Twelve subjects that presented with onychomycosis (seven female and five males with ages ranging from 28-68 years with an average of 50 years) received mechanical debridement followed by treatment with the short-pulsed Nd:YAG (1064nm) PinPointe FootLaser, which has proprietary micropulsing technology not present in long pulse Nd:YAG systems. Nine subjects received one treatment and three subjects received 2-3 treatments. Data following treatment was collected, reviewed and analyzed using planimetry measurements and ImageJ software.

All 12 subjects received extensive and thorough pretreatment mechanical debridement to remove the distal onycholytic nail plate and thin the nail plate to 1mm or less. The nail and surrounding area were cleaned of debris with chlorhexadine spray. Subjects then received treatment with the PinPointe laser. Each 1.5mm spot consisted of 10 micropulses over 0.5 seconds, delivering 20J/cm2 over 100 microseconds. Laser spots were administered in a grid pattern with 1.0-1.5mm spacing. Two passes were made using this technique, one transverse, and the other longitudinally, and included 2-3mm surrounding the nail. Of the subjects that received multiple treatments, two subjects received three treatments and one subject received two treatments administered at follow-up office visits.

Posttreatment, subjects are instructed to wash and dry between toes and treat any skin infection such as athlete’s foot until resolution. Use of a daily cream comprised of terbinafine 1%, was recommended for use all over the foot until completion. Afterwards, subjects may use 20g clotrimazole 1% cream. For long-term care, subjects are instructed to continue use of an antifungal cream daily or at least weekly. Followup visits were scheduled at an average of seven months following treatment, and photos were taken at baseline and at the follow-up visits in order to compare lesion reduction and the increase in clear nail area.


Planimetry analysis was used to assess lesion reduction and clear nail growth between pretreatment and post follow-up photos. To achieve consistent magnification, Adobe Photoshop was used by a technician to trace the area of clear nail and the area of infected nail. None of the photos were enhanced or filtered to obtain clear margins between infected and clear nail. To maintain consistency with measurements and evaluation, the following definitions were used:

  • Clear nail: uniform in color (pink, reddish, flesh, or pale) with smooth surface and normal thickness.
  • Infected nail: abnormal in color (milk white, black, brown, yellow, green) with flakey, distorted, roughened, ridges, or a thickened nail plate that may be onycholytic.
  • Lesion area: total infected area including discoloration, thickening and yellowing of nail
  • Lesion area at follow-up: total infected area at follow-up
  • Clear nail growth: new clear nail that has grown (%) in comparison to the baseline clear nail area
  • Absolute clear nail: the baseline lesion area (%) minus the follow-up lesion area (%)
  • Lesion reduction: the absolute lesion decrease % divided by the baseline lesion area (%)

ImageJ Software

The areas of infected and clear nail were calculated to compare baseline lesion area to the follow-up lesion using ImageJ software. ImageJ is a National Institutes of Health (NIH)-based program designed for image analysis and processing. The program converts images into their individual pixels so that different areas within the image can be analyzed.22 This new analysis tool has been used in several medical disciplines – to accurately count the number of organisms grown in culture,23 calculate microscopic changes in the kidney that occur with aging,24 and measure differences in muscle composition.25 ImageJ was utilized during the analysis to measure changes in clear nail growth between the baseline and follow-up images from subjects treated with the PinPointe FootLaser.


Due to the low efficacy and high degree of compliance required for oral and topical treatments for onychomycosis, there is a demand for alternative treatment options that are both effective and lack serious side effects. Laser treatments have been previously shown to be able to pass through the nail plate and onto the nail bed, heating it up sufficiently to damage and inhibit growth of onychomycosis-causing pathogens.26,27 This study evaluated the effectiveness of the micropulsing PinPointe FootLaser as an alternative treatment option for onychomycosis.

Improved foot care management of keeping nails clean and trimmed and shoes disinfected, reduced use of restrictive footwear, and increased cleanliness in and around the shower are important to the clinical outcome of patients. Therefore, it is important to consider these factors when evaluating the results of this study because they may have contributed to the success rate. Furthermore, although we found successful lesion reduction of 68% with just one treatment, because greater success rates were also found when given more than one treatment, further studies are required.

In this study, subjects showed significant improvement in clear nail area and a significant reduction in lesion area after a follow-up averaging seven months. Additionally, side effects of the PinPointe treatment were minimal and included minor discomfort during the procedure, but nothing that was intolerable, as all subjects were able to complete the procedure.


Our data suggests that the 1064nm Nd:YAG PinPointe FootLaser should be considered as an effective alternative therapy to the typical oral and topical medications. Furthermore, the treatment is quick and easy to incorporate into a practice, yielding high patient satisfaction and increased revenues.

Before and After Gallery

Hover your mouse over the images to pause the gallery. Click the arrows to navigate through the photos.



Our Legal Duty
We are required by applicable federal and state laws to maintain the privacy of your protected health information. We are also required to give you this notice about our privacy practices, our legal duties, and your rights concerning your protected health information. We must follow the privacy practices that are described in this notice while it is in effect. This notice takes effect April 14, 2003, and will remain in effect until we replace it.

We reserve the right to change our privacy practices and the terms of this notice at any time, provided that such changes are permitted by applicable law. We reserve the right to make the changes in our privacy practices and the new terms of our notice effective for all protected healthin formation that we maintain, including medical information we created or received before we made the changes.

You may request a copy of our notice (or any subsequent revised notice) at any time. For more information about our privacy practices, or for additional copies of this notice, please contact us using the information listed at the end of this notice.

Uses and Disclosures of Protected Health Information
We will use and disclose your protected health information about you for treatment, payment, and health care operations. Following are examples of the types of uses and disclosures of your protected health care information that may occur. These examples are not meant to be exhaustive, but to describe the types of uses and disclosures that maybe made by our office.

Treatment: We will use and disclose your protected health information to provide, coordinate or manage your healthcare and any related services. This includes the coordination or management of your health care with a third party. For example, we would disclose your protected health information, as necessary, to a home health agency that provides care to you. We will also disclose protected health information to other physicians who may be treating you. For example, your protected health information may be provided to a physician to whom you have been referred to ensure that the physician has the necessary information to diagnose or treat you.

In addition, we may disclose your protected health information from time to time to another physician or health care provider (e.g., a specialist or laboratory)who, at the request of your physician, becomes involved in your care by providing assistance with your health care diagnosis or treatment to your physician.

Payment: Your protected health information will be used, as needed, to obtain payment for your health care services. This may include certain activities that your health insurance plan may undertake before it approves or pays for the health care services we recommend for you, such as: making a determination of eligibility or coverage for insurance benefits, reviewing services provided to you for protected health necessity, and undertaking utilization review activities. For example, obtaining approval for a hospital stay may require that your relevant protected health information be disclosed to the health plan to obtain approval for the hospital admission.

Health Care Operations: We may use or disclose, as needed, your protected health information in order to conduct certain business and operational activities. These activities include, but are not limited to, quality assessment activities, employee review activities, training of students, licensing, and conducting or arranging for other business activities.

For example, we may use a sign-in sheet at the registration desk where you will be asked to sign your name. We may also call you by name in the waiting room when your doctor is ready to see you. We may use or disclose your protected health information, as necessary, to contact you by telephone or mail to remind you of your appointment.

We will share your protected health information with third party "business associates" that perform various activities (e.g., billing, transcription services) for the practice. Whenever an arrangement between our office and a business associate involves the use or disclosure of your protected health information, we will have a written contract that contains terms that will protect the privacy of your protected health information.

We may use or disclose your protected health information, as necessary, to provide you with information about treatment alternatives or other health-related benefits and services that may be of interest to you. We may also use and disclose your protected health information for other marketing activities. For example, your name and address may be used to send you a newsletter about our practice and the services we offer. We may also send you information about products or services that we believe may be beneficial to you. You may contact us to request that these materials not be sent to you.

Uses and Disclosures Based On Your Written Authorization:Other uses and disclosures of your protected health information will be made only with your authorization,unless otherwise permitted or required by law as described below.

You may give us written authorization to use your protected health information or to disclose it to anyone for any purpose. If you give us an authorization, you may revoke it in writing at any time. Your revocation will not affect any use or disclosures permitted by your authorization while it was in effect. Without your written authorization, we will not disclose your health care information except as described in this notice.

Others Involved in Your Health Care: Unless you object, we may disclose to a member of your family, a relative, a close friend or any other person you identify, your protected health information that directly relates to that person's involvement in your health care. If you are unable to agree or object to such a disclosure, we may disclose such information as necessary if we determine that it is in your best interest based on our professional judgment. We may use or disclose protected health information to notify or assist in notifying a family member, personal representative or any other person that is responsible for your care of your location, general condition or death.

Marketing: We may use your protected health information to contact you with information about treatment alternatives that may be of interest to you. We may disclose your protected health information to a business associate to assist us in these activities. Unless the information is provided to you by a general newsletter or in person or is for products or services of nominal value, you may opt out of receiving further such information by telling us using the contact information listed at the end of this notice.

Research; Death; Organ Donation: We may use or disclose your protected health information for research purposes in limited circumstances. We may disclose the protected health information of a deceased person to a coroner, protected health examiner, funeral director or organ procurement organization for certain purposes.

Public Health and Safety: We may disclose your protected health information to the extent necessary to avert a serious and imminent threat to your health or safety, or the health or safety of others. We may disclose your protected health information to a government agency authorized to oversee the health care system or government programs or its contractors, and to public health authorities for public health purposes.

Health Oversight: We may disclose protected health information to a health oversight agency for activities authorized by law, such as audits, investigations and inspections. Oversight agencies seeking this information include government agencies that oversee the health care system, government benefit programs, other government regulatory programs and civil rights laws.

Abuse or Neglect: We may disclose your protected health information to a public health authority that is authorized by law to receive reports of child abuse or neglect. In addition, we may disclose your protected health information if we believe that you have been a victim of abuse, neglect or domestic violence to the governmental entity or agency authorized to receive such information. In this case, the disclosure will be made consistent with the requirements of applicable federal and state laws.

Food and Drug Administration: We may disclose your protected health information to a person or company required by the Food and Drug Administration to report adverse events, product defects or problems, biologic product deviations; to track products; to enable product recalls; to make repairs or replacements; or to conduct post marketing surveillance, as required.

Criminal Activity: Consistent with applicable federal and state laws, we may disclose your protected health information, if we believe that the use or disclosure is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public. We may also disclose protected health information if it is necessary for law enforcement authorities to identify or apprehend an individual.

Required by Law: We may use or disclose your protected health information when we are required to do so by law. For example, we must disclose your protected health information to the U.S. Department of Health and Human Services upon request for purposes of determining whether we are in compliance with federal privacy laws. We may disclose your protected health information when authorized by workers' compensation or similar laws.

Process and Proceedings: We may disclose your protected health information in response to a court or administrative order, subpoena, discovery request or other lawful process,under certain circumstances. Under limited circumstances,such as a court order, warrant or grand jury subpoena, wemay disclose your protected health information to law enforcement officials.

Law Enforcement: We may disclose limited information to a law enforcement official concerning the protected health information of a suspect, fugitive, material witness, crime victim or missing person. We may disclose the protected health information of an inmate or other person in lawful custody to a law enforcement official or correctional institution under certain circumstances. We may disclose protected health information where necessary to assist law enforcement officials to capture an individual who has admitted to participation in a crime or has escaped from lawful custody.

Patient Rights
Access: You have the right to look at or get copies of your protected health information, with limited exceptions. You must make a request in writing to the contact person listed herein to obtain access to your protected health information. You may also request access by sending us a letter to the address at the end of this notice. If you request copies, we will charge you $25.00 for each page or$10.00 per hour to locate and copy your protected health information, and postage if you want the copies mailed to you. If you prefer, we will prepare a summary or an explanation of your protected health information for a fee. Contact us using the information listed at the end of this notice for a full explanation of our fee structure.

Accounting of Disclosures: You have the right to receive a list of instances in which we or our business associates disclosed your protected health information for purposes other than treatment, payment, health care operations and certain other activities after April 14, 2003. After April14, 2009, the accounting will be provided for the past six(6) years. We will provide you with the date on which we made the disclosure, the name of the person or entity to whom we disclosed your protected health information, a description of the protected health information we disclosed, the reason for the disclosure, and certain other information. If you request this list more than once in a12-month period, we may charge you a reasonable, cost-based fee for responding to these additional requests. Contact us using the information listed at the end of this notice for a full explanation of our fee structure.

Restriction Requests: You have the right to request that we place additional restrictions on our use or disclosure of your protected health information. We are not required to agree to these additional restrictions, but if we do, wewill abide by our agreement (except in an emergency). Any agreement we may make to a request for additional restrictions must be in writing signed by a person authorized to make such an agreement on our behalf. We will not be bound unless our agreement is so memorialized in writing.

Confidential Communication: You have the right to request that we communicate with you in confidence about your protected health information by alternative means or to an alternative location. You must make your request in writing. We must accommodate your request if it is reasonable, specifies the alternative means or location,and continues to permit us to bill and collect payment from you.

Amendment: You have the right to request that we amend your protected health information. Your request must be in writing, and it must explain why the information should be amended. We may deny your request if we did not create the information you want amended or for certain other reasons. If we deny your request, we will provide you a written explanation. You may respond with a statement of disagreement to be appended to the information you wanted amended. If we accept your request to amend the information, we will make reasonable efforts to inform others, including people or entities you name, of the amendment and to include the changes in any future disclosures of that information.

Electronic Notice: If you receive this notice on our website or by electronic mail (e-mail), you are entitled to receive this notice in written form. Please contact us using the information listed at the end of this notice to obtain this notice in written form.

Questions and Complaints
If you want more information about our privacy practices or have questions or concerns, please contact us using the information below. If you believe that we may have violated your privacy rights, or you disagree with a decision we made about access to your protected health information or in response to a request you made, you may complain to us using the contact information below. You also may submit a written complaint to the U.S. Department of Health and Human Services. We will provide you with the address to file your complaint with the U.S. Department of Health and Human Services upon request.

We support your right to protect the privacy of your protected health information. We will not retaliate in anyway if you choose to file a complaint with us or with the U.S. Department of Health and Human Services

Name of Contact Person: Midway Foot and Ankle
Telephone: 253-941-0887
Address: 26136 Pacific Highway South
Kent, WA